Targeting dna damage repair mechanisms in pancreas cancer

Lukas Perkhofer, Talia Golan, Pieter Jan Cuyle, Tamara Matysiak-Budnik, Jean Luc Van Laethem, Teresa Macarulla, Estelle Cauchin, Alexander Kleger, Alica K. Beutel, Johann Gout, Albrecht Stenzinger, Eric Van Cutsem, Joaquim Bellmunt, Pascal Hammel, Eileen M. O’reilly, Thomas Seufferlein

Research output: Contribution to journalArticlepeer-review


Impaired DNA damage repair (DDR) is increasingly recognised as a hallmark in pancreatic ductal adenocarcinoma (PDAC). It is estimated that around 14% of human PDACs harbour mutations in genes involved in DDR, including, amongst others, BRCA1/2, PALB2, ATM, MSH2, MSH6 and MLH1. Recently, DDR intervention by PARP inhibitor therapy has demonstrated effectiveness in germline BRCA1/2-mutated PDAC. Extending this outcome to the significant proportion of human PDACs with somatic or germline mutations in DDR genes beyond BRCA1/2 might be beneficial, but there is a lack of data, and consequently, no clear recommendations are provided in the field. Therefore, an expert panel was invited by the European Society of Digestive Oncology (ESDO) to assess the current knowledge and significance of DDR as a target in PDAC treatment. The aim of this virtual, international expert meeting was to elaborate a set of consensus recommendations on testing, diagnosis and treatment of PDAC patients with alterations in DDR pathways. Ahead of the meeting, experts completed a 27-question survey evaluating the key issues. The final recommendations herein should aid in facilitating clinical practice decisions on the management of DDR-deficient PDAC.

Original languageEnglish
Article number4259
Issue number17
StatePublished - 1 Sep 2021


  • BRCA1/2
  • DNA damage repair
  • Homologous repair deficiency
  • Pancreatic ductal adenocarcinoma
  • PARP inhibition
  • Platinum


Dive into the research topics of 'Targeting dna damage repair mechanisms in pancreas cancer'. Together they form a unique fingerprint.

Cite this